EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens



Predictive value of activated tyrosine kinase (Tyr1248) in patients with HER2-overexpressing metastatic breast cancer (MBC) treated with trastuzumab + chemotherapy regimens



European Journal of Cancer Supplements 2(3): 173-174




(PDF emailed within 0-6 h: $19.90)

Accession: 063299968

Download citation: RISBibTeXText

DOI: 10.1016/s1359-6349(04)91006-3



Related references

Predictive value of activated tyrosine kinase in patients with HER2-overexpressing metastatic breast cancer treated with trastuzumab + chemotherapy regimens. EJC Supplements 2(3): 173-174, March, 2004

Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy. Journal of Clinical Oncology 26(15_suppl): 1053-1053, 2016

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). European Journal of Cancer 43(4): 725-735, 2007

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. Journal of Korean Medical Science 24(5): 910-917, 2010

Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 4(5): 329-37; Discussion 338-9, 2004

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Journal of Clinical Oncology 26(15_suppl): 1130-1130, 2016

Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. International Journal of Clinical Oncology 14(1): 48-52, 2009

Brain metastases (BM) in patients treated with trastuzumab for HER2 overexpressing metastatic breast cancer (MBC): Incidence and survival. Journal of Clinical Oncology 23(16_suppl): 1568-1568, 2016

Clinical significance of brain metastases occurrence in HER2 overexpressing metastatic breast cancer patients treated with trastuzumab. Journal of Clinical Oncology 24(18_suppl): 10593-10593, 2016

Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy. Breast Cancer Research & Treatment 64(1): 123, November, 2000

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Annals of Oncology 20(6): 1026-1031, 2009

Trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer: Pilot study. Journal of Clinical Oncology 23(16_suppl): 803-803, 2016

PTEN, EGFR, MAPK and Akt status by immunohistochemistry (IHC) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) +/- chemotherapy (CT): correlation with clinical outcome. 2007

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Cancer Journal 21(5): 357-364, 2016

Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy. 2007